EverSource Wealth Advisors LLC Acquires 156 Shares of Illumina, Inc. (NASDAQ:ILMN)

EverSource Wealth Advisors LLC boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 16.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,108 shares of the life sciences company’s stock after acquiring an additional 156 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Illumina were worth $148,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Golden State Wealth Management LLC bought a new stake in shares of Illumina during the fourth quarter valued at approximately $32,000. Versant Capital Management Inc lifted its holdings in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after buying an additional 146 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new position in Illumina in the 4th quarter valued at $45,000. Assetmark Inc. increased its stake in shares of Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after buying an additional 296 shares during the period. Finally, TD Private Client Wealth LLC lifted its stake in shares of Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after acquiring an additional 141 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on ILMN. Citigroup decreased their price target on Illumina from $130.00 to $90.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Canaccord Genuity Group lowered their price target on shares of Illumina from $135.00 to $115.00 and set a “hold” rating for the company in a research report on Tuesday, March 11th. Barclays restated an “underweight” rating on shares of Illumina in a report on Tuesday, March 11th. Stephens reaffirmed an “overweight” rating and set a $156.00 target price on shares of Illumina in a report on Tuesday, March 11th. Finally, Piper Sandler increased their price target on Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $140.90.

Illumina Stock Performance

ILMN opened at $85.68 on Tuesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The company has a market capitalization of $13.57 billion, a price-to-earnings ratio of -11.16, a P/E/G ratio of 1.60 and a beta of 1.17. The business’s 50-day moving average price is $112.46 and its two-hundred day moving average price is $129.53. Illumina, Inc. has a 1 year low of $80.18 and a 1 year high of $156.66.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.